Bezuclastinib

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

Phase 3 Peak study shows bezuclastinib combined with sunitinib improves outcomes in gastrointestinal stromal tumors (GIST) compared to sunitinib alone.

Recent developments in the Gastrointestinal Stromal Tumors (GIST) treatment pipeline highlight significant progress, with over 25 companies actively developing more than 28 pipeline drugs. Key players like Jiangsu Hengrui Medicine, Novartis, and Daiichi Sankyo Company are advancing promising therapies, including Famitinib, Nilotinib, and DS 6157, through various stages of clinical trials.

Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.

Bezuclastinib 100mg demonstrates a favorable safety profile with mostly low-grade, reversible adverse events in patients with non-advanced systemic mastocytosis.